EU5 Dental Implants & Abutments Market Outlook to 2033 - Dental Abutments and Dental Implants
Summary
GlobalData’s “EU5 Dental Implants & Abutments Market Outlook to 2033” is a comprehensive databook report, covering key market data on the EU5 Dental Implants & Abutments market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Dental Abutments and Dental Implants
The EU5 Dental Implants & Abutments Market report provides key information and data on -
Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2023 company share and distribution share data for Dental Implants & Abutments Market.
Global corporate-level profiles of key companies operating within the EU5 Dental Implants & Abutments Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Scope
EU5 Dental Implants & Abutments is segmented as follows -
Dental Abutments
Dental Implants
Reasons to Buy
EU5 Dental Implants & Abutments Market report helps you to develop -
Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what’s the most preferred mode of product distribution -
11.1.2 Feb 12, 2024: Bittium Expands Its Range of Supported ECG Analysis Software by Collaborating With a Service Partner
11.1.3 Dec 20, 2023: Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy
11.1.4 Oct 13, 2023: Elos Medtech Notice to Attend the Extraordinary General Meeting
11.1.5 Sep 01, 2023: Neoss Group Welcomes Sandra von Schmudde as New Managing Director of Neoss GmbH
11.2 Financial Announcements
11.2.1 Mar 21, 2024: Lytix Biopharma Announces the Publication of a Paper Describing How Ltx-315 Mediates Antitumor Activity Through Multiple Pathways
11.2.2 Feb 26, 2024: Transthera Initiates IND-Enabling Studies for TT-02332, a Novel, Highly Potent and CNS-Penetrating NLRP3 Inhibitor
11.2.3 Jan 10, 2024: HemoSonics' Quantra Hemostasis System with QStat Cartridge Wins 2024 Business Intelligence Group (BIG) Innovation Award in Healthcare Category
11.2.4 Nov 06, 2023: PYC and FDA Align on Clinical Trial Pathway In ADOA
11.2.5 Oct 19, 2023: Elos Medtech Announces Interim Report 1 January - 30 September, 2023
11.2.6 Aug 03, 2023: Straumann Group Announces Invitation of Half Year Results 2023
11.3 Government and Public Interest
11.3.1 Dec 13, 2023: AbClone Secures Additional Funds to Expedite Clinical Trials For CARTI treatment